Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various autoimmune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. The Company is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis. It is also involved in the development of cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its Thykamine is an active lead drug candidate with safety and profiles confirmed in several pre-clinical and clinical studies targeting inflammation. Its cosmeceutical products include R-Spinasome and Purgenesis. The Company’s subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand-name pharmaceutical companies.